

Seracam® Abstract Accepted at SNMMI on Sentinel Lymph Node Biopsy Imaging Study

London, UK, 4 April 2025. Serac Imaging Systems Limited ("Serac Imaging Systems" or "the Company"), the medtech company developing 'Seracam®' a portable hybrid gamma-optical camera for medical imaging, announces that an abstract submitted by its clinical partner at the University of Malaya Medical Centre in Malaysia has been accepted for presentation at the prestigious Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 21-24 June in New Orleans, USA.

An abstract titled "SeracamTM hybrid optical-gamma camera for intraoperative imaging in breast cancer management: Preliminary results from a prospective trial" presents findings comparing the use of Seracam® to a standard gamma probe in sentinel lymph node biopsy procedures in breast cancer patients. It is authored by Aik Hao Ng, Intan Noorliyana Md Musidek, Mohammad Nazri Md Shah and Mee Hoong See from the Faculty of Medicine at the University of Malaya, Chai Hong Yeong from the Faculty of Health and Medical Sciences, Taylor's University, Malaysia and Alan Perkins from the University of Nottingham, UK.

The 20 patient study is ongoing and is expected to complete later this year.

- ENDS -

For more information, please contact:

Mark Rosser, Chief Executive Officer +44 (0)20 8948 0000

info@seraclifesciences.com

Francetta Carr, Communications +44 (0)7711 010 820

<u>francettacarr@seraclifesciences.com</u>

Notes to Editors

About Serac Imaging Systems and Seracam®

Serac Imaging Systems Ltd is a medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingsystems.com

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.

About SNMMI 2025: https://snmmi.org/AM